Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Reads0
Chats0
TLDR
Modulation of cdk activity is an attractive target for cancer chemotherapy, and several agents that modulatecdk activity are in or are approaching entry into clinical trials.Abstract:
In the last decade, the discovery and cloning of the cyclin-dependent kinases (cdks), key regulators of cell cycle progression, have led to the identification of novel modulators of cdk activity. Initial experimental results demonstrated that these cdk modulators are able to block cell cycle progression, induce apoptotic cell death, promote differentiation, inhibit angiogenesis, and modulate transcription. Alteration of cdk activity may occur indirectly by affecting upstream pathways that regulate cdk activity or directly by targeting the cdk holoenzyme. Two direct cdk modulators, flavopiridol and UCN-01, are showing promising results in early clinical trials, in which the drugs reach plasma concentrations that can alter cdk activity in vitro. Although modulation of cdk activity is a well-grounded concept and new cdk modulators are being assessed for clinical testing, important scientific questions remain to be addressed. These questions include whether one or more cdks should be inhibited, how cdk inhibitors should be combined with other chemotherapy agents, and which cdk substrates should be used to assess the biologic effects of these drugs in patients. Thus, modulation of cdk activity is an attractive target for cancer chemotherapy, and several agents that modulate cdk activity are in or are approaching entry into clinical trials.read more
Citations
More filters
Journal ArticleDOI
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
TL;DR: This review provides an overview of deregulation of the cell cycle in cancer by focusing on mechanisms, i.e. regulation of cyclin‐dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events.
Journal ArticleDOI
To cycle or not to cycle: a critical decision in cancer.
TL;DR: Tumour cells undergo uncontrolled proliferation, yet tumours most often originate from adult tissues, in which most cells are quiescent, so the proliferative advantage of tumour cells arises from their ability to bypass quiescence.
Journal ArticleDOI
Protein kinase inhibitors: insights into drug design from structure.
TL;DR: This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available and which have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site, and into targeting noncatalytic domains.
Journal ArticleDOI
Role of cell cycle in mediating sensitivity to radiotherapy.
TL;DR: This work describes how cell cycle and DNA damage checkpoint control relates to exposure to ionizing radiation and suggests that one way in which chemotherapy and fractionated radiotherapy may work better is by partial synchronization of cells in the most radiosensitive phase of the cell cycle.
Journal ArticleDOI
Cyclin D-dependent kinases, INK4 inhibitors and cancer.
TL;DR: A series of mouse models have been developed to study the in vivo function of individual components of this pathway in both normal homeostasis and tumor development, and several novel molecules, such as Cdk inhibitors, are under development as potential anti-cancer drugs.
References
More filters
Journal ArticleDOI
CDK inhibitors: positive and negative regulators of G1-phase progression
TL;DR: This work challenges previous assumptions about how the G1/S transition of the mammalian cell cycle is governed, helps explain some enigmatic features of cell cycle control that also involve the functions of the retinoblastoma protein (Rb) and the INK4 proteins, and changes the thinking about how either p16 loss or overexpression of cyclin D-dependent kinases contribute to cancer.
Journal ArticleDOI
Cancer Cell Cycles
TL;DR: Genetic alterations affecting p16INK4a and cyclin D1, proteins that govern phosphorylation of the retinoblastoma protein and control exit from the G1 phase of the cell cycle, are so frequent in human cancers that inactivation of this pathway may well be necessary for tumor development.
Journal ArticleDOI
The regulation of E2F by pRB-family proteins
TL;DR: The rapid growth in the size of the E2F literature hides the fact that several fundamental questions have not been fully answered, and the second section of this review details five unresolved issues that have been highlighted by recent publications.
Journal ArticleDOI
Cyclin-dependent kinases: engines, clocks, and microprocessors.
TL;DR: This work has shown that Cdk activity is governed by a complex network of regulatory subunits and phosphorylation events whose precise effects on Cdk conformation have been revealed by recent crystallographic studies.
Journal Article
Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents
Julian Adams,Vito J. Palombella,Edward A. Sausville,Jill R. Johnson,Antonia T. Destree,Douglas Lazarus,Jochen Maas,Christine S. Pien,Samuel Prakash,Peter J. Elliott +9 more
TL;DR: The data show that inhibition of this target site by PS-341 results in reduced tumor growth in murine tumor models and highlight that the proteasome is a novel biochemical target and that inhibitors such asPS-341 represent a unique class of antitumor agents.